TP53 and neoplasm: Despite the fact that the energy metabolism function of myeloid cells was significantly hindered in KRAS/TP53 mutant cancers, the glycolysis function of TAMs did not appear to be substantially reduced (Figure 5K), suggesting adaptation of TAMs to the KRAS/TP53 mutant tumor microenvironment.